For healthcare professionals

Arti­cle 1 – Overview

The Thea Pas­sion­ate about Preser­v­a­tive Free’ cam­paign is designed to encour­age thought, dis­cus­sion and shar­ing of best prac­tice in oph­thal­mol­o­gy eye care between March 20th 2021 and Sep­tem­ber 30th 2021.

Par­tic­i­pants present clin­i­cal cas­es they were involved in and which demon­strate an improve­ment to a patient involv­ing the change from pre­served eye drops to preser­v­a­tive free eye drops.

Cas­es are sub­mit­ted to a nation­al selec­tion board of oph­thal­mol­o­gists, which selects the 3 best pre­sen­ta­tions. 3 prizes of unre­strict­ed edu­ca­tion­al grants of £1000 are available.

Reg­is­tra­tion and case study sub­mis­sions are made online at www​.thea​-phar​ma​cu​ti​cals​.co​.uk/​p​r​e​s​e​r​v​a​t​i​v​e​-free.

Arti­cle 2 – Participants

Can­di­dates must be UK based reg­is­tered health­care pro­fes­sion­als work­ing in eye care.

A can­di­date can only sub­mit one case.

Arti­cle 3 – Sub­mis­sion of case

The case report can involve one or sev­er­al patients.

Sub­mit­ted cas­es must be orig­i­nal (i.e. not pre­vi­ous­ly pub­lished). The case can include pre­sen­ta­tions, diag­noses and/​or man­age­ment of ocu­lar dis­ease and must be relat­ed to the ben­e­fit of preser­v­a­tive free med­ica­tions on the eye and the wider ben­e­fit to the patient.

A ded­i­cat­ed web­site will inform the can­di­dates of the rules of the con­test. Can­di­dates have to reg­is­ter online and sub­mit their case writ­ten in Eng­lish on this web­site before Sep­tem­ber 30th2021.

The case must be sub­mit­ted by the can­di­date who must be the author and should not be sub­mit­ted by any­one else on their behalf. Co-authors can be declared how­ev­er the grant will be attrib­uted exclu­sive­ly to the main author who sub­mit­ted the case.

The author must declare any com­pet­ing interests.

When sub­mit­ting their pre­sen­ta­tion online, the candidate:

  • cer­ti­fies that they have legal capac­i­ty to par­tic­i­pate in the contest;
  • shall not breach any con­fi­den­tial­i­ty agree­ment with their employ­er or any oth­er third party;
  • ful­ly accepts the cur­rent rules;
  • cer­ti­fies that they were per­son­al­ly and direct­ly involved in the man­age­ment of the case;
  • cer­ti­fies that the sub­mit­ted case is orig­i­nal and has not been pre­vi­ous­ly published ;
  • cer­ti­fies they have any and all autho­riza­tion and approval to include the cor­re­spond­ing doc­u­men­ta­tion (pho­tos, video, etc.) in the case report
  • shall indem­ni­fy, defend and hold Thea Phar­ma­ceu­ti­cals harm­less from and against any and all third par­ty claims, suits, pro­ceed­ings, dam­ages, costs, lia­bil­i­ties and expens­es (includ­ing, with­out lim­i­ta­tion, rea­son­able attor­neys’ fees) aris­ing from their neg­li­gence or will­ful mis­con­duct in con­nec­tion with the Pas­sion­ate about Preser­v­a­tive Free mission.

If there is any inter­est which might be con­sid­ered prej­u­di­cial to the inde­pen­dence of a can­di­date, such con­flict of inter­ests should lead to the rejec­tion of the candidate.

Sub­ject to UK leg­is­la­tion or to any code of con­duct regard­ing med­ical pro­fes­sion­als in the UK, the can­di­date cer­ti­fies that such reg­u­la­tion doesn’t pre­vent him/​her from par­tic­i­pat­ing in the con­test, in par­tic­u­lar in con­sid­er­a­tion of his/​her sta­tus as res­i­dent. Should UK reg­u­la­tions require that the can­di­date declares or asks pri­or approval for his/​her par­tic­i­pa­tion in the con­test, the can­di­date shall be respon­si­ble for such dec­la­ra­tion and shall keep avail­able to THEA the proof of such procedure.


Thea Phar­ma­ceu­ti­cals shall com­ply with applic­a­ble UK law, reg­u­la­tion or code of con­duct regard­ing the dec­la­ra­tion to a med­ical coun­cil or any com­pe­tent enti­ty where the res­i­dent or fel­low is reg­is­tered and with the report­ing and dec­la­ra­tion to a pub­lic audi­ence or a com­pe­tent author­i­ty of any inter­ests it may have with the res­i­dent or fellow.

Arti­cle 4 – Case structure

The pre­sen­ta­tion should be writ­ten in Eng­lish in Word for­mat. Illus­tra­tion of the case by pic­tures and imag­ing is rec­om­mend­ed. A max­i­mum of 10 pages is allowed. The clin­i­cal case should be divid­ed into the fol­low­ing sec­tions (in this order):

  • Title page: with the title of the case with­out iden­ti­fi­ca­tion of the author.
  • Intro­duc­tion: The intro­duc­tion sec­tion should explain the back­ground of the case, includ­ing the dis­or­der, usu­al pre­sen­ta­tion and pro­gres­sion and an expla­na­tion of the pre­sen­ta­tion and the rel­e­vant side effects and effect of these on the qual­i­ty of life of the patient(s).
  • Case pre­sen­ta­tion with illus­tra­tions and fig­ures: The case pre­sen­ta­tion should con­tain a descrip­tion of the patient’s rel­e­vant demo­graph­ic infor­ma­tion (with­out adding any details that could lead to the iden­ti­fi­ca­tion of the patient); any rel­e­vant med­ical his­to­ry of the patient; the patient’s symp­toms and signs; any tests that were car­ried out and a descrip­tion of any treat­ment or inter­ven­tion. If it is a case series, then details must be includ­ed for all patients. Cas­es can include clin­i­cal pho­tographs, pro­vid­ed these are accom­pa­nied by writ­ten con­sent to pub­lish from the patient(s) or are com­plete­ly anony­mous. Details of preser­v­a­tive-relat­ed tox­i­c­i­ty man­i­fes­ta­tion and effect on qual­i­ty of life should be added.
  • Dis­cus­sion: This is for addi­tion­al com­ments that pro­vide any addi­tion­al rel­e­vant infor­ma­tion not includ­ed in the case pre­sen­ta­tion, and that put the case in con­text or that explain spe­cif­ic treat­ment decisions.
  • Con­clu­sion: A brief con­clu­sion of what can be learned from the case report and what the clin­i­cal impact will be/​was. Infor­ma­tion should be includ­ed on how it could advance knowl­edge and aware­ness of pre­served drop side effects and their impact on patients. This sec­tion should state clear­ly the main con­clu­sions of the case report and give a clear expla­na­tion of their impor­tance and relevance.


The full author’s name, qual­i­fi­ca­tions, insti­tu­tion­al address­es, cur­rent posi­tion they hold at insti­tu­tions or soci­eties, or any oth­er rel­e­vant back­ground infor­ma­tion and email address­es must not be includ­ed in the case pre­sen­ta­tion to ensure anony­mous and impar­tial judg­ing of the submission.

The pre­sen­ta­tion and appen­dix (image, fig­ures, illus­tra­tions ‚…) shall:

  • be anony­mous
  • not infringe upon the pri­va­cy or per­son­al rights of others
  • not con­tain any sen­si­tive information
  • not be the copy­right of any oth­er enti­ty unless this is acknowledged

Arti­cle 5 – Process

The selec­tion of the best cas­es will be com­plet­ed before 1st Decem­ber 2021

Win­ners will be noti­fied by email.

The nation­al jury will have access to all clin­i­cal cas­es through the website. 

Con­tes­tants will remain anony­mous until the end of the con­test. To ensure an inde­pen­dent and fair vote, ini­tials will be allo­cat­ed to each sub­mis­sion. These ini­tials will be used through­out the entire process and will not be dis­closed to the con­tes­tant nor the juries.

Thea Phar­ma­ceu­ti­cals will not release any infor­ma­tion that might help iden­ti­fy the con­tes­tants. Like­wise, mem­bers of the juries will remain anony­mous to the contestants.

The eval­u­a­tion will be based on the fol­low­ing cri­te­ria to obtain a final mark out of one hundred:

  • orig­i­nal­i­ty
  • clar­i­ty
  • demon­stra­tion of con­tri­bu­tion to patient qual­i­ty of life
  • illus­tra­tions

The board shall select the win­ners in Novem­ber 2021. The deci­sion of the jury will be final and binding.

Win­ners will be informed by email before Decem­ber 1st 2021


Arti­cle 6 – Impor­tant dates

Sep­tem­ber 30th, 2021 – dead­line for sub­mis­sion of the cas­es Novem­ber 2021 – selec­tion of the best cas­es by nation­al juries Decem­ber 2021 — award of unre­strict­ed edu­ca­tion­al grant

Arti­cle 7 – Awards

Cas­es of each win­ner will be pub­lished on the Thea UK website.

All best cas­es will be pub­lished in mate­ri­als cre­at­ed and pub­lished by Thea and dis­trib­uted at con­gress­es, online via our web­site and may be used for oth­er edu­ca­tion­al and pro­mo­tion­al purposes.

Arti­cle 9 – Intel­lec­tu­al property

Thea Phar­ma­ceu­ti­cals reserves the right to use and repro­duce the clin­i­cal cas­es with the pic­tures includ­ed and the name and pho­to­graph of par­tic­i­pants in order to orga­nize pub­lic rela­tions activities. 

For this pur­pose, by accept­ing the present terms and con­di­tions, the Par­tic­i­pant express­ly and irrev­o­ca­bly grants to Thea Phar­ma­ceu­ti­cals a roy­al­ty free, irrev­o­ca­ble and world­wide license to use all or parts of the intel­lec­tu­al prop­er­ty rights (writ­ing, draw­ings and mod­els, pic­tures, etc.) arisen from the estab­lish­ment of the case report. 

This license is grant­ed for the legal dura­tion of pro­tec­tion of the licensed rights as defined by the UK Pas­sion­ate about Preser­v­a­tive Free 2021.

Intel­lec­tu­al Prop­er­ty Code.

The licensed rights per­tain­ing to the case report includes notably:

  • The repro­duc­tion right, mean­ing the right to repro­duce or to have repro­duced, in a num­ber at THEA’s con­ve­nience, the ele­ments of the case report either in

whole or in part, on any known or unknown tan­gi­ble sup­ports, such as paper for­mat or elec­tron­ic format;

  • The right of rep­re­sen­ta­tion, which is the right to release or to have released pub­licly the ele­ments of the case report either in whole or in part, either alone or asso­ci­at­ed with oth­er ele­ments, by any tan­gi­ble means, includ­ing on the Inter­net; this right notably implies the rights for Thea Phar­ma­ceu­ti­cals to pub­lish, dif­fuse, and edit any doc­u­ment con­tain­ing the ele­ments of the case report either in whole or in part;
  • The right of adap­ta­tion which is the right to direct­ly or indi­rect­ly adapt the ele­ments of the case either in whole or in part on any sup­ports, includ­ing notably the right to mod­i­fy them and to insert them into oth­er doc­u­ments or elements;
  • The right to trans­late into any lan­guage includ­ing com­put­er lan­guage the ele­ments of the case either in whole or in part.

The par­tic­i­pant declares to be the sole hold­er of the intel­lec­tu­al prop­er­ty rights on the con­tents of the ele­ments of the case report and declares that the afore­said the ele­ments of the case report do not include any repro­duc­tion and/​or adap­ta­tion of any work of the mind of third par­ties in whole or in part or more gen­er­al­ly, any repro­duc­tion and/​or adap­ta­tion of any right of third parties.

Arti­cle 10 – Data privacy

All per­son­al data about the can­di­dates will remains anony­mous to the jury(ies) until the end of the contest.

Par­tic­i­pants agree that per­son­al data, espe­cial­ly name and address, may be processed, shared, and oth­er­wise used by Thea Phar­ma­ceu­ti­cals for the pur­pos­es and with­in the con­text of the Pas­sion­ate about Preser­v­a­tive Free mission 

and any oth­er pur­pos­es out­lined here­in. The data may also be used by Thea Phar­ma­ceu­ti­cals in order to ver­i­fy the participant’s iden­ti­ty, postal address, and tele­phone num­ber or to oth­er­wise ver­i­fy the participant’s eli­gi­bil­i­ty to par­tic­i­pate in the contest.

Par­tic­i­pants have the right to access, review, rec­ti­fy, can­cel or delete any per­son­al data held by Thea Phar­ma­ceu­ti­cals by writ­ing to Thea Phar­ma­ceu­ti­cals Ltd IC5, Keele Uni­ver­si­ty Sci­ence & Inno­va­tion Park, Keele, Stafford­shire IC5 5NT.


Arti­cle 11 – Mod­i­fi­ca­tion of the rules

Thea Phar­ma­ceu­ti­cals reserves the right to amend the arti­cles of these rules, with­out notice, main­ly to reflect changes in leg­is­la­tion, judi­cial deci­sions, new reg­u­la­to­ry rules, and rec­om­men­da­tions made by orga­ni­za­tions respon­si­ble for the admin­is­tra­tion of the Internet.

Every mod­i­fi­ca­tion will be announced on the Thea UK website.

Arti­cle 12 – Miscellaneous 

The present rules are con­strued under UK law.

Any and all dis­putes aris­ing from the inter­pre­ta­tion of these rules shall be set­tled ami­ca­bly. In case of per­sis­tent dis­agree­ment on their appli­ca­tion, and the absence of agree­ment, any dis­pute shall be exclu­sive­ly set­tled by the com­pe­tent courts of the UK.

In the event that any pro­vi­sion of these rules shall be found to be unlaw­ful, void or, for any rea­son, unen­force­able, such pro­vi­sion shall be deemed sev­ered from, and shall in no way affect the valid­i­ty or enforce­abil­i­ty of the remain­ing provisions.

Download a copy of the terms and conditions